Meet the TRANSFORM Lead researchers

With decades of research-funding experience, we’ve brought together the best UK researchers and engaged independent, international experts to make sure the trial is robust enough and can provide the insight needed to revolutionise prostate cancer diagnosis.

The trial’s six lead researchers represent four of the UK’s biggest research centres and are experts in fields such as statistics, imaging and genetics that will be vital to TRANSFORM.

But they won’t work alone. They’ll be supported by a trial management group of researchers and clinicians with skills in areas from behavioural sciences to pathology.

By bringing together a team with this range of skills that cover all aspects of a clinical trial, we can help ensure that TRANSFORM gets the high-quality evidence we need to underpin a national screening programme.

Professor Hashim Ahmed

Professor Hashim Ahmed, Chair of Urology at Imperial College London, is a researcher and clinician who studies how biopsies, imaging techniques and treatments can be improved for men with prostate cancer.

Professor Rhian Gabe

Professor Rhian Gabe, Professor of Biostatistics and Clinical Trials at Queen Mary University of London, is a statistician with expertise in clinical trials as well as cancer screening, prevention and early detection.

Professor Rosalind Eeles

Professor Rosalind Eeles, Professor of Oncogenetics at The Institute of Cancer Research, London, is a geneticist who has helped find more than 160 genetic differences that contribute to a man’s risk of prostate cancer.

Professor Rakesh Heer

Professor Rakesh Heer, Chair of Urology at Imperial College London, is a surgeon and researcher with a focus on urological cancers and expertise spanning stem cells and basic biology to robotic surgery and clinical trials. Professor Heer Leads the development of TRANSFORM Discovery.

Professor Caroline Moore

Professor Caroline Moore, NIHR Research Professor and Head of Urology at University College London, specialises in using MRI scanning to detect and treat prostate cancer, and personalising men's journeys from screening to treatment.

Professor Mark Emberton

Professor Mark Emberton, Professor of Interventional Oncology at University College London, works to improve diagnosis and treatment for men using new imaging techniques and less-invasive treatments.